HGF and Miyoshi myopathy: Our findings oppose to the studies of Pour, and Svachova et al. who suggested the role of HGF as a predictive factor for MM treatment response using ASCT, conventional therapy, and thalidomide or bortezomib-based regimens [19, 20].